Esperion Therapeutis.Inc. buy marge
Summary
This prediction ended on 20.12.18 with a price of €39.95. The BUY prediction by marge for Esperion Therapeutis.Inc. performed very badly with a performance of -43.06%. marge has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 0.000% | 0.000% | 72.793% | 91.494% |
| iShares Core DAX® | 1,00 % | 4,83 % | 8,15 % | 62,60 % |
| iShares Nasdaq 100 | 2,70 % | -1,72 % | 26,92 % | 88,13 % |
| iShares Nikkei 225® | 3,52 % | -3,51 % | 48,06 % | 78,11 % |
| iShares S&P 500 | 1,77 % | 1,27 % | 23,58 % | 70,47 % |
Comments by marge for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
marge stimmt der Buy-Einschätzung von Maxi-Scalibusa zu
marge stimmt am 07.03.2018 der Buy-Einschätzung von Maxi-Scalibusa mit dem Kursziel 231,5$ zu.
Überschrift: Hot Stock